Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ILB-3101
- Development stage
- Phase 1
- Lead developer
- Innolake Biopharma
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) developed by Innolake Biopharm for the treatment of solid tumors, particularly those expressing B7-H3 (CD276 antigen), an immune checkpoint protein overexpressed in a broad spectrum of malignant tumors. The drug consists of an anti-B7H3 monoclonal antibody conjugated to the potent microtubule inhibitor eribulin via a proprietary linker. Its mechanism involves targeted delivery of eribulin to tumor cells, resulting in inhibition of tubulin polymerization and subsequent cell cycle arrest and apoptosis. Preclinical studies have demonstrated strong tumor-killing activity and favorable pharmacokinetic/toxicity profiles. Clinical development is ongoing, with phase 1/2 trials underway for advanced malignant solid neoplasms and IND approvals for acute myeloid leukemia and advanced cancer in China[2][4][5].
- Other names
- ILB 3101ILB3101ILB-3101
02
Targets
TUBB (Tubulin (alpha and beta subunits))B7-H3
Beyond the preview
Go deeper on ILB-3101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ILB-3101.